Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
TBPH
TBPH
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TBPH News
Wall Street Analysts Adjust Ratings
6d ago
Benzinga
Wall Street Analysts Adjust Ratings on Key Stocks
6d ago
Benzinga
Theravance Biopharma's Phase 3 Trial Fails to Meet Primary Endpoint
Mar 03 2026
Benzinga
Theravance Biopharma Cuts Workforce by 50% Amid Phase 3 Trial Failure
Mar 03 2026
stocktwits
U.S. Stocks Decline Amid Ongoing Iran-U.S. Conflict
Mar 03 2026
Benzinga
Theravance Biopharma Halts Clinical Program for Ampreloxetine
Mar 03 2026
seekingalpha
Theravance Biopharma Halts Ampreloxetine Program Following Phase 3 Study Failure
Mar 03 2026
PRnewswire
Theravance Biopharma's CYPRESS Study Fails to Meet Primary Endpoint
Mar 03 2026
Newsfilter
THERAVANCE BIOPHARMA INC ANNOUNCES COMPLETE R&D ORGANIZATION WIND-DOWN AND AROUND 50% REDUCTION IN G&A STAFF
Mar 03 2026
moomoo
THERAVANCE BIOPHARMA INC ANTICIPATES RESTRUCTURING WILL YIELD ANNUAL CASH FLOW OF ABOUT $60 - $70 MILLION
Mar 03 2026
moomoo
THERAVANCE BIOPHARMA INC: RESTRUCTURING INITIATIVE AIMED AT CUTTING COSTS BY ABOUT 60% (AROUND $70 MILLION)
Mar 03 2026
moomoo
THERAVANCE BIOPHARMA INC: PHASE 3 CYPRESS STUDY FAILED TO ACHIEVE PRIMARY OBJECTIVE
Mar 03 2026
moomoo
Theravance Biopharma Announces Phase 3 CYPRESS Study Failed to Achieve Primary Endpoint; Board Initiates Strategic Review and Implements Cost-Cutting Measures
Mar 03 2026
moomoo
Irenic Capital Reduces Stake in Papa John's International
Feb 22 2026
Fool
Atossa Therapeutics Receives FDA Orphan Drug Designation, Stock Rises Nearly 13%
Jan 20 2026
NASDAQ.COM
Cyclerion Therapeutics Expands Collaboration with Medsteer, Shares Surge 44.2%
Jan 06 2026
Benzinga
Show More News
